Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing data of SK-BR-3 Parental vs lapatinib resistance (LR) cells

ABSTRACT: RNA sequencing data of SK-BR-3 Parental vs lapatinib resistance (LR) cells

PROVIDER: PRJNA646412 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12226700_1.fastq.gz	Fastqsanger.gz
	SRR12226700_2.fastq.gz	Fastqsanger.gz
	SRR12226699_1.fastq.gz	Fastqsanger.gz
	SRR12226699_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

RNA sequencing data of SK-BR-3 Parental vs lapatinib resistance (LR) cells

Project description:Transcriptional profiling of SK-BR-3 lapatinib resistance cells comparing control SK-BR-3 parental cells. Randomly fragmented the purified RNA for sequencing with a short read and reverse-transcrived. Attached different adapters to both end of cDNA and ligated them and amplified. Calculate the amount of expression obtained by transcript quantification of each sample as a normalization value considering transcript length and depth of coverage.

2022-07-31 | GSE154470 | GEO

Lapatinib-Induced Enhancement Of Mitochondrial Respiration In HER2-Positive SK-BR-3 Cells: Mechanism Revealed By Analysis Of Proteomic But Not Transcriptomic Data

Project description:Dual inhibitors of HER2 and EGFR, such as lapatinib, have shown significant efficacy for the therapy of HER2-positive breast cancer. Previous experiments showed that in cell cultures, the efficacy of lapatinib was significantly reduced by exposure to human serum and human epidermal growth factor (EGF). At the proteomic and transcriptomic levels, we examined the changes in the HER2-positive breast cancer cell line SK-BR-3 profiles upon treatment with lapatinib, either alone or in combination with human serum or EGF. Proteomic profiling revealed 350 differentially expressed proteins (DEPs) in response to lapatinib treatment at concentrations that induced cell growth arrest. Addition of human serum or EGF in combination with lapatinib prevented cell growth inhibition, and this combination treatment returned the expression of ~93% of DEPs to drug-free levels for both human serum and EGF. Gene ontology enrichment and OncoboxPD pathway activation level analysis showed that lapatinib addition influenced mostly common functional processes revealed in RNA- and protein-based assays. However, a specific feature was observed at the proteome level: addition of lapatinib increased the expression of proteins associated with mitochondrial function and cellular respiration. This feature was not observed when using RNA sequencing data for the same experiments. However, it is consistent with the results of the resazurin test, which showed a 1.8-fold increase in SK-BR-3 cellular respiration upon exposure to lapatinib. Thus, we conclude that enhanced cellular respiration is a novel additional mechanism of action of lapatinib on HER2-positive cancer cells.

2024-09-26 | PXD054180 | Pride

Human breast cancer cells: parental v.s lapatinib-resistant clone

Project description:Transcriptional profiling of human HER2-positive BT474 breast cancer cells comparing control untreated cancer cells with lapatinib-resistant clone established by chronic treatment with lapatinib Two-condition experiment, parental cells vs. lapatinib-resistant (LR) clone.

2013-10-31 | E-GEOD-51889 | biostudies-arrayexpress

Screening target genes of miR-100 in MGC-803 and SK-BR-3 cells

Project description:We tried to find the target genes of miR-100 in MGC-803 and SK-BR-3 cells, thus we uesd specific miR-100 inhibitor to knock down the level of miR-100 in the cells, with this condition, we used this mRNA microarray to find the genes whose amount changed. and they may be the target genes that miR-100 mediated. Total of four chips, MGC-AMO, MGC-NC, SK-AMO, SK-NC. MGC and SK represents MGC-803 and SK-BR-3 cells respectively. AMO is the specific miR-100 inhibitor and NC is negative control.

2014-01-09 | E-GEOD-53909 | biostudies-arrayexpress

Expression data from mutant p53 breast cancer cell line SK-BR-3

Project description:Tumor associated mutant p53 proteins often gain new functions for tumorigenesis and tumor progression. It has been shown that mutant p53 can transcriptionally regulate a group of genes, which in turn contributes to mutant p53 gain of function. A mutant p53 interacting protein Pontin binds to mutant p53 and promotes its gain of function. This experiment tests whether the interaction of Pontin with mutant p53 regulates the transcriptional activity of mutant p53. We used a breast cancer cell line containing endogenous mutant p53 (SK-BR-3) with or without knockdown of mutant p53 by shRNA to identify genes regulated by mutant p53. We then knocked down endogenous Pontin in SK-BR-3 cells, and compared the transcriptional levels of these genes in cells with and without mutant p53 knockdown to investigate the effect of Pontin on mutant p53-dependent transcriptional regulation.

2015-06-01 | GSE58140 | GEO

Screening target genes of miR-100 in MGC-803 and SK-BR-3 cells

2014-01-09 | GSE53909 | GEO

Acquired resistance to lapatinib

Project description:These studies are aimed at understanding gene expression chnages in a Her2 positive breast cancer cell line that has developed acquired resistance to lapatinib. Samples include SKBR3 parental and resistant (SKBR3-R) under basal conditions and in response to 0.1 and 1uM lapatinib treatment after 24 hours.

2012-06-30 | GSE38376 | GEO

Human breast cancer cells: parental v.s lapatinib-resistant clone

2013-10-31 | GSE51889 | GEO

Genome-wide analysis of GW3965-responsive genes in 4 different breast cancer cell lines, MCF-7, T-47D, SK-BR-3, and MDA-MB-231

Project description:Analysis of differentially expressed genes in response to the LXR agonist GW3965 in the MCF-7, T-47D, SK-BR-3, and MDA-MB-231 breast cancer cell lines. It was previously reported that GW3965 has antiproliferative effects on these 4 different breast cancer cell lines. In the present study, we additionally determine the effects of the LXR ligand on breast cancer cells and determine their mechanism of action in reducing cell proliferation. Total RNA obtained from 4 different breast cancer cell lines (MCF-7, T-47D, SK-BR-3, MDA-MB-231) grown in culture treated with ethanol (control) or GW3965 (GW-treated, experimental) for 48 hours. Triplicates were performed.

2013-07-17 | E-GEOD-34987 | biostudies-arrayexpress

Genome-wide analysis of GW3965-responsive genes in 4 different breast cancer cell lines, MCF-7, T-47D, SK-BR-3, and MDA-MB-231

2013-07-17 | GSE34987 | GEO